Stock News

Plancorp Trimmed By $404,302 Its Emerson Elec Co (EMR) Position; Last Week Atara Biotherapeutics, Inc. (ATRA) Analysts

Plancorp Llc decreased Emerson Elec Co (EMR) stake by 2.38% reported in 2017Q3 SEC filing. Plancorp Llc sold 6,521 shares as Emerson Elec Co (EMR)’s stock declined 4.02%. The Plancorp Llc holds 267,489 shares with $16.81M value, down from 274,010 last quarter. Emerson Elec Co now has $46.34B valuation. The stock increased 2.08% or $1.49 during the last trading session, reaching $72.99. About 4.78 million shares traded or 33.13% up from the average. Emerson Electric Co. (NYSE:EMR) has risen 18.47% since February 20, 2017 and is uptrending. It has outperformed by 1.77% the S&P500.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Atara Biotherapeutics had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The company was initiated on Friday, October 9 by William Blair. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Sell” rating given on Thursday, September 15 by Goldman Sachs. On Tuesday, December 15 the stock rating was downgraded by Citigroup to “Sell”. Jefferies maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Thursday, August 31. Jefferies has “Buy” rating and $30.0 target. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Neutral” rating by Goldman Sachs on Wednesday, November 18. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Sell” rating given on Friday, August 19 by Citigroup. The rating was reinitiated by Jefferies with “Buy” on Thursday, June 22. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Wednesday, September 9 by Canaccord Genuity. JMP Securities maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Tuesday, December 15. JMP Securities has “Market Outperform” rating and $40 target. The stock has “Buy” rating by Jefferies on Monday, October 24. See Atara Biotherapeutics, Inc. (NASDAQ:ATRA) latest ratings:

15/02/2018 Broker: Citigroup Old Rating: Neutral New Rating: Sell Downgrade
30/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $70.0 Maintain
26/01/2018 Broker: Cowen & Co Rating: Outperform Initiates Coverage On
03/01/2018 Broker: Citigroup Old Rating: Sell New Rating: Neutral Upgrade
29/12/2017 Broker: Goldman Sachs Rating: Hold New Target: $19.0
31/08/2017 Broker: Jefferies Rating: Buy New Target: $30.0 Maintain

Since August 22, 2017, it had 0 buys, and 14 sales for $5.79 million activity. Another trade for 4,400 shares valued at $64,438 was sold by Ciechanover Isaac E.. Turner Heather D had sold 12,214 shares worth $464,210. Shares for $86,100 were sold by Haqq Christopher on Monday, October 16. 37,000 shares were sold by MCGRATH JOHN, worth $900,815.

The stock decreased 3.51% or $1.65 during the last trading session, reaching $45.4. About 810,307 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since February 20, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.71 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.26, from 1.28 in 2017Q2. It improved, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. 431,050 are owned by State Street. American International Group holds 0% or 17,080 shares. Essex Inv Mgmt Lc has 0.06% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Citigroup Inc reported 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Legal General Grp Incorporated Public Limited Co invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Harbourvest Partners Limited Liability Company accumulated 10,543 shares. Ameritas Investment Prtn reported 1,810 shares or 0% of all its holdings. 25,520 are owned by Deutsche Bank Ag. State Board Of Administration Of Florida Retirement System reported 10,253 shares stake. Alliancebernstein L P, a New York-based fund reported 27,740 shares. 18,791 were accumulated by Invesco. 600,000 were accumulated by Artal Grp Sa. Swiss Commercial Bank reported 28,600 shares. California State Teachers Retirement System, California-based fund reported 40,323 shares. Credit Suisse Ag has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Among 29 analysts covering Emerson Electric Co. (NYSE:EMR), 12 have Buy rating, 2 Sell and 15 Hold. Therefore 41% are positive. Emerson Electric Co. had 86 analyst reports since August 6, 2015 according to SRatingsIntel. Canaccord Genuity maintained Emerson Electric Co. (NYSE:EMR) rating on Wednesday, August 5. Canaccord Genuity has “Hold” rating and $52 target. Vertical Research upgraded the shares of EMR in report on Wednesday, August 26 to “Hold” rating. The rating was downgraded by TheStreet to “Hold” on Friday, September 4. The firm earned “Neutral” rating on Thursday, August 4 by UBS. As per Monday, April 18, the company rating was maintained by Barclays Capital. On Tuesday, April 19 the stock rating was maintained by Citigroup with “Sell”. The rating was upgraded by Buckingham Research on Tuesday, December 13 to “Neutral”. Stifel Nicolaus maintained the shares of EMR in report on Wednesday, August 2 with “Buy” rating. On Tuesday, February 6 the stock rating was maintained by Robert W. Baird with “Hold”. The rating was initiated by Citigroup with “Sell” on Thursday, January 21.

Leave a Reply

Your email address will not be published. Required fields are marked *